Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients

BackgroundKi67 is a biomarker of proliferation to be used in immunohistochemistry (IHC)-based surrogate assay to determine the necessity of cytotoxic therapy for Luminal-like breast cancer patients. cyclinD1 is another frequently used biomarker of proliferation. A retrospective study was performed h...

Full description

Bibliographic Details
Main Authors: Junmei Hao, Wenfeng Zhang, Yan Lyu, Jiarui Zou, Yunyun Zhang, Jiahong Lyu, Jianbo Zhang, Shuishan Xie, Cuiping Zhang, Jiandi Zhang, Fangrong Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
QDB
FFPE
Ki67
Luminal-like
breast cancer
cyclin D1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.737794/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.737794/full

Similar Items